Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9)
- PMID: 31902148
- PMCID: PMC6943272
- DOI: 10.4093/dmj.2019.0205
Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9)
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Comment in
-
Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582-9).Diabetes Metab J. 2019 Dec;43(6):915-916. doi: 10.4093/dmj.2019.0213. Diabetes Metab J. 2019. PMID: 31902151 Free PMC article. No abstract available.
Comment on
-
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus.Diabetes Metab J. 2019 Oct;43(5):582-589. doi: 10.4093/dmj.2018.0124. Epub 2019 Jan 16. Diabetes Metab J. 2019. PMID: 30688048 Free PMC article.
References
-
- Ko SH, Han K, Lee YH, Noh J, Park CY, Kim DJ, Jung CH, Lee KU, Ko KS TaskForce Team for the Diabetes Fact Sheet of the Korean Diabetes Association. Past and current status of adult type 2 diabetes mellitus management in Korea: a national health insurance service database analysis. Diabetes Metab J. 2018;42:93–100. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
